2-Chloro-N6-cyclopentyladenosine (CCPA), an adenosine A1 receptor agonist, suppresses ethanol withdrawal syndrome in rats.
The ability of 2-chloro-N6-cyclopentyladenosine (CCPA) to suppress ethanol withdrawal syndrome was tested in male rats rendered physically dependent on ethanol by intragastric administrations of ethanol (12-18 g/kg daily for 6 days). CCPA administered 24 hr after the last ethanol dose produced a dose-dependent inhibition of withdrawal signs such as tremors and audiogenically induced seizures, an effect prevented by the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX).
Concas
A
A
Department of Experimental Biology, University of Cagliari, Italy.
Cuccheddu
T
T
Floris
S
S
Mascia
M P
MP
Biggio
G
G
D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000430:Alcohol Withdrawal Delirium / Q000503:physiopathology*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D008297:Male; D009460:Neurologic Examination; D051381:Rats; D017207:Rats, Sprague-Dawley; D018047:Receptors, Purinergic P1 / Q000187:drug effects* / Q000502:physiology
D018047:Receptors, Purinergic P1; C058394:2-chloro-N(6)cyclopentyladenosine; D000241:Adenosine